ImmunityBio Inc Ordinary Shares IBRX
News
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio Gets First Anktiva Authorization in Asia
ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva
